Effects of ibesartan plus perindopril on patients with chronic congestive heart failure

Objective To evaluate the safety and efficacy of ibesartan plus perindopril in patients with congestive heart failure(CHF). Methods Ninety six patients with CHF were randomized to treatment group(n= 48) which received perindopril 2～8mg/d plus ibesartan 37.5～150mg/d or control group(n=48) which received perindopril 2～8mg/d besides conventional treatment. After twenty four weeks therapy,functional class,echocardiographic variables,blood potassium,urea nitrogen and creatinine were compared between two groups. Results After twenty four weeks therapy,6-min walk-test,left atrial diameter,end-diastolic volume(EDV) of the left ventricle(LV),end-systolic volume(ESV)of LV,left ventricular ejection fraction(LVEF),fraction shortening(FS),cardiac output(CO) and cardiac index(CI) and heart function improved significantly in two groups(control group: t=2.55,2.04,2.98,3.39,2.58,3.24,3.07,3.28; treatment group: t=2.35,2.14,3.08,3.29,2.56,3.22,3.05,3.18,P0.05). However,treatment group had a more significant improvement in 6-min walk-test,LVEDV,LVESV,LVEF and FS than that of controls (t=2.88,2.20,3.04,2.75,3.19,P0.05). The cardiac function of treatment group improved significantly compared with the controls (χ2=4.85,P 0.05). The differences of blood potassium,urea nitrogen and creatinine before and after treatment in the two groups were not significant(control group: t=3.41,4.22,3.86; treatment group: t=3.46,4.38,3.89,P0.05). Conclusions The study suggests that perindopril plus ibesartan in the treatment of CHF is safe,and more effective than perindopril alone.